Industry News
Biotechnology Industry News
Mersana Therapeutics’ decision…
Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid off.
Zealand is pausing development on…
Zealand is pausing development on its dual GLP-1/GLP-2 agonist, known as dapiglutide, as it strives to focus its time and money on “programs with the greatest potential for clinical differentiation and long-term value creation,” the
Korro Bio delivered a double…
Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the
A phase 3 trial of Novartis’…
A phase 3 trial of Novartis’ next-generation malaria treatment has met its primary endpoint, positioning the drugmaker to seek approval of a therapy with the potential to kill drug-resistant parasites.
After forming from a merger hashed…
After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and deprioritizing the research spearheaded by one of its founding companies.
In a highly anticipated article,…
In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved.
AbbVie is ending an 11-year…
AbbVie is ending an 11-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat.
Who would have predicted that one…
Who would have predicted that one of the hottest trends for beleaguered biotechs in 2025 would be to rebrand as a crypto company?
One in four safety-related…
One in four safety-related failures are due to central nervous system (CNS) toxicity.
Alkermes has reported another…
Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its hopes of being first to market in the indication.
Bayer has cleared out four cancer…
Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion Therapeutics.
A quarter of Metagenomi’s…
A quarter of Metagenomi’s employees, including the company’s CEO, are set to lose their jobs after the gene editing biotech decided to focus resources on its preclinical hemophilia A program.
Pfizer on Monday unveiled seven…
Pfizer on Monday unveiled seven near-term trials of its PD-1xVEGF bispecific antibody, the first of what chief oncology officer Jeff Legos, Ph.D., called “many planned waves” of clinical investigation into the asset. These include a
Novo Nordisk has reported the…
Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam, BridgeBio and Pfizer.
As Neuphoria Therapeutics…
As Neuphoria Therapeutics considers its options in the wake of the failure of its phase 3 social anxiety program, an investor has swooped in with one potential escape route.
Another of the psychiatry drugs…
Another of the psychiatry drugs Neurocrine licensed from Takeda has stumbled in the clinic.
CeleCor presented the results of…
CeleCor presented the results of its pivotal CeleBrate phase 3 trial in a late-breaking session at the the American Heart Association’s annual scientific sessions.
Voyager Therapeutics is shoving…
Voyager Therapeutics is shoving off on a new journey to discover and develop small molecules targeting protein bundles that contribute to neurodegenerative diseases. Voyager is paying travel partner Transition Bio a single-digit million-dollar upfront payment,
Cogent Biosciences has cleared…
Cogent Biosciences has cleared another phase 3 hurdle for its lead asset, bezuclastinib, teeing up an FDA approval in submission for a gastrointestinal cancer in the first half of next year.
Iambic will use the funds to…
Iambic will use the funds to continue its recent pipeline progress with a focus on bringing two of its programs to the clinic.